Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aurinia Pharmaceuticals Inc AUPH

Healthcare Biotechnology
Aurinia Pharmaceuticals Inc. is a Canada-based fully integrated biopharmaceutical company. The Company is focused on delivering therapies to treat targeted patient populations with a high unmet medical need that are impacted by autoimmune, kidney and rare diseases. The Company has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis... see more

Recent & Breaking News (NDAQ:AUPH)

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

Newsfile April 27, 2022

Shareholder Action Notice: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 27, 2022

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aurinia Pharmaceuticals Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 14, 2022 - (NASDAQ: AUPH)

PR Newswire April 27, 2022

AUPH LAWSUIT ALERT: Levi & Korsinsky Notifies Aurinia Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Newsfile April 26, 2022

AUPH Stock News: Robbins LLP Investigates Aurinia Pharmaceuticals Inc. (AUPH) on Behalf of Shareholders

Business Wire April 26, 2022

Shareholder Action Reminder: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 26, 2022

AUPH ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 14, 2022 in the Class Action Filed on Behalf of Aurinia Pharmaceuticals Inc. Shareholders

PR Newswire April 26, 2022

AUPH SHAREHOLDER ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

Newsfile April 25, 2022

AUPH LAWSUIT ALERT: Levi & Korsinsky Notifies Aurinia Pharmaceuticals Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Newsfile April 25, 2022

Investor Action Notice: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 25, 2022

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Aurinia Pharmaceuticals Inc. Investors of a Lead Plaintiff Deadline of June 14, 2022

PR Newswire April 25, 2022

INVESTOR ALERT: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AUPH

PR Newswire April 23, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aurinia Pharmaceuticals Inc., of Class Action Lawsuit and Upcoming Deadline - AUPH

PR Newswire April 23, 2022

DEADLINE: Aurinia Pharmaceuticals Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - AUPH

Business Wire April 22, 2022

ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

Newsfile April 22, 2022

Aurinia Pharmaceuticals Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 14, 2022 to Discuss Your Rights - AUPH

Newsfile April 22, 2022

Investor Action Alert: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 22, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aurinia Pharmaceuticals Inc., of Class Action Lawsuit and Upcoming Deadline - AUPH

Newsfile April 21, 2022

ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPH

PR Newswire April 21, 2022

Bronstein, Gewirtz & Grossman, LLC Notifies Aurinia Pharmaceuticals Inc. (AUPH) Investors of Class Action and Encourages Investors to Contact the Firm

Business Wire April 21, 2022